Acquisition

A chessboard with blocks that read MA
Pharma

After trial fail, Teravance is bought out by Zymeworks for $929M

Four months after Theravance Biopharma signaled it was up for sale, the Dublin-based company has agreed to be bought out by Zymeworks for $929 million.
Kevin Dunleavy Jun 29, 2026 11:30am
MA mergers and acquisitions deal handshake buyout

Esperion to go private in potential $1.1B buyout by ArchiMed

May 1, 2026 11:26am
Biogen

Biogen lays out $5.6B to acquire Apellis

Mar 31, 2026 10:32am
Servier

Servier rounds out rare cancer offerings with $2.5B Day One buy

Mar 6, 2026 10:14am
more expensive
Favicon Fierce Biotech

China is no longer licensing 'bargain basement': analyst

Feb 24, 2026 5:07pm
MA
Favicon Fierce Biotech

4 trends driving biopharma M&A this year, per Bain

Jan 28, 2026 5:00pm